Treatment of locally advanced non-small-cell lung cancer (NSCLC) in the elderly is challenging, with many available treatment options from radiotherapy alone to sequential chemoradiation. The latest phase III trial comparing radiotherapy alone with concurrent chemoradiation reported a survival improvement for the combination; however, this does not define a new standard treatment.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Aupèrin, A. et al. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. Ann. Oncol. 17, 473–483 (2006).
Aupèrin, A. et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advance non-small-cell lung cancer. J. Clin. Oncol. 28, 2181–2190 (2010).
Movsas, B. et al. The benefit of treatment intensification is age and histology dependent in locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of Radiation Therapy Oncology Group (RTOG) chemoradiation studies. Int. J. Radiat. Oncol. Biol. Phys. 45, 1143–1149 (1999).
Werner-Wasik, M. et al. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival. Int. J. Radiat. Oncol. Biol. Phys. 48, 1475–1482 (2000).
Langer, C. J. et al. Effect of advanced age on outcome in Radiation Therapy Oncology Group studies of locally advanced NSCLC. Lung Cancer 29 (Suppl. 1), 104 (2000).
Langer, C. J. et al. Elderly patients with locally advanced non-small cell lung cancer benefit from combined modality therapy: secondary analysis of Radiation Therapy Oncology Group (RTOG) 94–10 [abstract 1193]. Proc. Am. Soc. Clin. Oncol. 21, a299 (2002).
Schild, S. E. et al. The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J. Clin. Oncol. 21, 3201–3206 (2003).
Atagi, S. et al. Standard thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with locally advanced non-small cell lung cancer: a phase III trial of Japan Clinical Oncology Group (JCOG9812). Jpn J. Clin. Oncol. 35, 195–201 (2005).
Atagi, S. et al. Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomized, controlled, phase III trial by the Japan Clinical Oncology Group (JCOG0301). Lancet Oncol. doi:10.1016/S1470–2045(12)70139–0.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Gridelli, C. Locally advanced NCSLC in the elderly: which treatment?. Nat Rev Clin Oncol 9, 434–435 (2012). https://doi.org/10.1038/nrclinonc.2012.112
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2012.112
